Liquid calories are fluids consumed as part of your daily diet that often go unnoticed and...
NASH Rapidly Overtaking Hepatitis C as a Cause of Liver Cancer
Rock Climbing: Lose Weight on the Wall
If your weight loss efforts have hit a wall, why not climb it? Rock climbing is becoming an...
Weight Watchers vs. Medical Weight Loss Programs in Scottsdale: Comparing the Results
Many residents in Scottsdale, Phoenix, and Glendale struggle with weight loss plateaus despite...
Arizona Medical Weight Loss Programs vs Online Programs: Which One Provides the Best Results?
The weight loss landscape has shifted significantly with the rise of digital health platforms....
Is Brown Rice Healthier Than White Rice?
Is brown rice better than white rice? Intuitively, one would think that brown rice is much...
Tirzepatide vs. Semaglutide: Which Weight Loss Medication is Better?
Modern medical weight loss has been changed by the arrival of highly effective prescription...
Comments on article NASH rapidly overtaking hepatitis C as cause of liver cancer
BY BIANCA NOGRADY FROM THE JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY
I recently read this article and it struck me as something we should be paying more attention to.
Definitions
“NAFLD” describes hepatic steatosis with hepatocyte fat accumulation in a liver without inflammation.
“NASH” describes fat accumulation, hepatic inflammation and hepatocyte injury with or without fibrosis or cirrhosis.
Facts from the Article:
- NAFLD develops in the absence of significant alcohol abuse, hereditary disorders or causative medications and is often associated with obesity.
- The prevalence of NAFLD in the US is estimated to be 30-46% and is the most common form of liver disease in Western countries.
- The clinical predictors of advanced fibrosis in NAFLD include: hypertension, diabetes mellitus and visceral obesity.
- In 2015 NASH was the number one indication for liver transplantation in patients aged <50 years (surpassing HCV infection)!
- Weight loss of 3% can decrease hepatic steatosis (NAFLD), 5% can decrease inflammation (NASH), 7% can resolve NASH and 10% can regress fibrosis!
As Obesity Medicine physicians, we see patients with NAFLD/NASH every day. I have seen many patients with elevations in LFTs that normalize within several months of treatment. Not to mention the resolution of hypertension and DM2 as risk factors for NAFLD/NASH.










